Neuronetics is trading at $2.02 (-5.16%), with no specific fresh company catalyst identified. - No specific Neuronetics announcement explaining the October 13 decline surfaced in the search; its investor-relations releases page showed earlier releases, not a new alert-day announcement. - Healthcare-sector weakness may have been a backdrop: XLV was down 1.37%, while major indexes were only modestly lower. Available evidence does not establish a direct cause for Neuronetics’ move.